AI Quick Summary

🔍 Meet the Residents Across Our SI Parks! 🔎🌐 Let's shine a spotlight on @GliaPharm SA, resident at @Campus Biotech Geneva, site of @Switzerland Innovation Park West EPFL. 🔬GliaPharm was created in 2016 as a spinoff company from the laboratory of Prof. Pierre Magistretti at @EPFL, a leading research laboratory in the field of brain metabolism and glial cell biology. The company stands at the forefront of Alzheimer's disease research with an innovative therapeutic approach to target glial cells to promote brain metabolism and neuroprotection. 🌟 “GliaPharm’s innovative therapeutic approach is to target glial cells, the cells primarily responsible for glucose uptake into the brain, and increase energy delivery to the brain and enhance brain energy metabolism that is defective in pathological conditions such as Alzheimer’s disease,” says Prof. @Pierre J. Magistretti, GliaPharm’s scientific founder. 🚀The company secured a substantial $4.2M investment from the @Alzheimer's Drug Discovery Foundation (ADDF), a significant boost propelling their leading compound towards clinical advancements.🤝 Their synergy within the rich innovation environment at Campus Biotech underscores the collective pursuit of addressing healthcare challenges and shaping the future of neurology research.🔗 Read the article in the “@24 heures” (in French and for subscribers only: https://www.24heures.ch/un-labo-genevois-ouvre-une-voie-nouvelle-contre-alzheimer-521302166449#SwitzerlandInnovation #WhySwitzerland #Alzheimers #Biote

Post Metadata

• Author: Switzerland Innovation Digital
• Published Date: 7/25/2024 11:47:04 AM
• Modified Date: 9/24/2024 12:31:56 PM

Post Description

🔍 Meet the Residents Across Our SI Parks! 🔎

🌐 Let's shine a spotlight on @GliaPharm SA, resident at @Campus Biotech Geneva, site of @Switzerland Innovation Park West EPFL.

🔬GliaPharm was created in 2016 as a spinoff company from the laboratory of Prof. Pierre Magistretti at @EPFL, a leading research laboratory in the field of brain metabolism and glial cell biology. The company stands at the forefront of Alzheimer's disease research with an innovative therapeutic approach to target glial cells to promote brain metabolism and neuroprotection.

🌟 “GliaPharm’s innovative therapeutic approach is to target glial cells, the cells primarily responsible for glucose uptake into the brain, and increase energy delivery to the brain and enhance brain energy metabolism that is defective in pathological conditions such as Alzheimer’s disease,” says Prof. @Pierre J. Magistretti, GliaPharm’s scientific founder.

🚀The company secured a substantial $4.2M investment from the @Alzheimer's Drug Discovery Foundation (ADDF), a significant boost propelling their leading compound towards clinical advancements.

🤝 Their synergy within the rich innovation environment at Campus Biotech underscores the collective pursuit of addressing healthcare challenges and shaping the future of neurology research.

🔗 Read the article in the “@24 heures” (in French and for subscribers only: https://www.24heures.ch/un-labo-genevois-ouvre-une-voie-nouvelle-contre-alzheimer-521302166449

#SwitzerlandInnovation #WhySwitzerland #Alzheimers #Biote